强大的肝热带mRNA脂质纳米颗粒:通过低密度脂蛋白受体通过ApoE介导的输送 独立的吸收机制
Ashish Sarode1, Christian Ortiz1, Tadeh Derstepanian1
1mRNA Center of Excellence, Sanofi, Waltham, MA, 02451, USA.
Advanced materials (Deerfield Beach, Fla.)
|November 29, 2025
概括
这项研究开发了强大的信使RNA-脂质纳米粒子 (mRNA-LNP) 配方,以有效地传递肝脏. 优化的配方实现了治疗性蛋白质表达,毒性最小,为遗传疾病治疗奠定了基础.
科学领域:
- 生物技术是生物技术.
- 药物运输 药物运输 药物运输
- 遗传医学是一种遗传医学.
背景情况:
- 非病毒传递系统对于核酸疗法至关重要,但有效的有效载荷传递到目标器官仍然是一个挑战.
- 脂质纳米粒子 (LNP) 配方影响药物的生物分布,细胞吸收和治疗疗效,但潜在的机制需要进一步了解.
- 甲尼丁转糖胺酶 (OTC) 缺乏症作为蛋白质替代疗法的模型,以调查肝脏特异性输送.
研究的目的:
- 开发具有强大的mRNA-LNP配方,增强肝脏热带性.
- 阐明控制LNP肝脏向和细胞吸收的机制.
- 建立基于mRNA的蛋白质替代疗法用于罕见遗传疾病的平台.
主要方法:
- 针对LNP配方的可电离和辅助脂质的系统选.
- 优化LNP的组成和制造工艺.
- 生物物理特征的LNP,包括阿波利波蛋白E (ApoE) 的结合.
- 在临床前模型中评估细胞吸收机制和*in vivo*治疗疗效.
主要成果:
- 鉴定1,2-dierucoyl-sn-glycero-3-phosphoethanolamine (DEPE) 作为一种肝热带辅助脂质,通过调节LNP结构和ApoE结合来增强肝特异的输送.
- 发现了一种新型的可电离性脂质,其核心为N-(2-Hydroxyethyl) -piperazine-N'-(4-butanesulfonic acid) (HEPBS),可以独立于低密度脂蛋白受体 (LDLR) 途径进行有效的细胞吸收.
- 在临床前模型中实现了强大的剂量响应,持续的治疗性OTC蛋白表达,在临床前模型中具有最小的毒性,由稳定的肝功能和细胞因子水平证明.
结论:
- 获得了对LNP肝脏热带性和细胞吸收途径的机械洞察力.
- 优化的mRNA-LNP配方显示出有效的蛋白质替代疗法的潜力.
- 开发的平台支持mRNA疗法的更广泛应用,用于需要肝脏基因表达的遗传疾病.
相关概念视频
Receptor-mediated Endocytosis
110.4K
Overview
110.4K
Bioavailability Enhancement: Drug Permeability Enhancement
176
Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
176
Carrier-Mediated Transport
981
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
981
Regulation of Nuclear Protein Sorting
3.2K
Nuclear protein sorting regulates nucleus composition and gene expression, crucial for determining the fate of a eukaryotic cell. Hence, the entry and exit of molecules across the nuclear envelope is a tightly controlled process. Nuclear protein sorting can be inhibited by one of the following ways: 1) masking cargo signal sequences, 2) modifying the nuclear receptor's affinity for cargo, 3) controlling the nuclear pore size, 4) retaining the cargo during its transit to the cytosol or the...
3.2K
Drug Absorption Mechanism: Carrier-Mediated Membrane Transport
5.7K
Certain large, lipid-insoluble drug molecules that resemble amino acids, peptides, or glucose, require specialized carrier proteins to facilitate their diffusion across cell membranes. This transport can occur through either facilitated diffusion, which does not require energy input, or active transport, which does require energy input.
Facilitated diffusion is a passive process that utilizes human Solute Carrier (SLC) transporters. These transporters bind to the drug, undergo structural...
Facilitated diffusion is a passive process that utilizes human Solute Carrier (SLC) transporters. These transporters bind to the drug, undergo structural...
5.7K


